Protection From Cisplatin Ototoxicity by Lactated Ringers

• Status: Withdrawn
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Lactated Ringer's solution is effective in patients undergoing chemotherapy with cisplatin for head and neck cancer in regards to cisplatin-induced hearing loss.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma
• Treatments: Cisplatin; Levofloxacin; Ofloxacin

Criteria

Inclusion Criteria:

• Patients with cancer to be treated with cisplatin.

• Patients expected to receive a minimum of 3 rounds of chemotherapy.

• Patients receiving a minimum dose of cisplatin of 70 mg/m2

Exclusion Criteria:

• Patients who have had middle ear surgery.

• Patients who have active external or middle ear disease

• Patients who have preceding pure tone average of >40 dB HL